Update: Data on the responses of neurons and astrocytes to oxidative injury in the presence of insulin-like growth factor I

Fig1a) Neuron viability measured as percentage of GFP positive cells cultured ± astrocytes after treatment with H2O2. N: neurons, NA: neurons + astrocytes. Names for each file refer to the related figures in the associated research article.
Fig1b) IGF-I measured in the supernatant of neuron or astrocyte cultures treated ± with H2O2.
Fig1c) UPDATED with additional data: pAKT levels measured in astrocytes transfected with an IGF-IR dominant negative construct (IGF-IR DN) after treatment with IGF-I.
Fig1d) Neuron viability measured as percentage of GFP positive cells cultured with astrocytes transfected with IGF-IR DN.
Fig2a) pAKT levels in astrocytes treated ± with PPP (picropodophyllin) after treatment with IGF-I.
Fig2b) Neuron viability measured as percentage of GFP positive cells treated ± with PPP and H2O2.
Fig2c) Neuron viability expressed as percentage of GFP positive cells cultured with astrocytes and treated ± with PPP and H2O2.
Fig2d) Neuron viability measured as percentage of GFP positive cells cultured with astrocytes (both cells types from forebrain) and treated ± with PPP and H2O2.
Fig2e) Neuron viability measured as percentage of GFP positive cells cultured with astrocytes and treated with IGF-I, H2O2 or both.
Fig3a) Neuron death measured as percentage of PI positive cells treated ± with IGF-I and H2O2.
Fig3b) Astrocyte survival expressed as percentage of PI negative cells treated ± with IGF-I and H2O2.
Fig3c) FOXO activity from astrocytes treated with IGF-I, H2O2 or both.
Fig3d) Cell survival expressed as percentage of GFP positive cells for astrocytes transfected with wt or AKT-insensitive mutant FOXO, treated ± with IGF-Iand H2O2.
Fig3e) pAKT levels form astrocytes treated with IGF-I I ± H2O2.
Fig4a) Mitochondrial O2- measured in astrocytes treated ± with IGF-I and H2O2.
Fig4b) Total ROS (reactive oxygen species) measured in astrocytes treated ± with IGF-I and H2O2.
Fig5a) Cu/Zn SOD (superoxide dismutase) levels from astrocytes treated with IGF-I, H2O2 or both.
Fig5b) Mn SOD levels from astrocytes treated with IGF-I, H2O2 or both.
Fig6a) TXNIP levels from astrocytes treated with IGF-I, H2O2 or both.
Fig6b) Cell survival from astrocytes transfected with TXNIP shRNA ± H2O2.
Fig6c) TXNIP levels from neurons treated with IGF-I, H2O2 or both.
Fig6d) TXNIP levels from astrocytes pre-treated with the calcium inhibitor BAPTA in the presence of IGF-I, H2O2 or both.
Fig7a) SCF (stem cell factor) mRNA from astrocytes treated with IGF-I, H2O2 or both.
Fig7b) Neuron viability measured as percentage of GFP positive cells treated with IGF-I, SCF or both in the presence of H2O2.
Fig7c) pERK levels form astrocytes treated with IGF-I, SCF or both ± H2O2.
Fig7d) SCF and IGF-I mRNA from control or MCAO (medial cerebral artery occlusion) animal cortex (contralateral or ispsilateral cortex).
Fig7e) SCF protein levels from control or MCAO animal cortex (contralateral or ispsilateral cortex).
Luminol) Reactive oxygen species (ROS) measurements using luminol (which detects superoxide anions)

图1a) 以绿色荧光蛋白（GFP）阳性细胞培养百分比衡量神经元的存活率，±星形胶质细胞在H2O2处理后的情况。N：神经元，NA：神经元+星形胶质细胞。每个文件的名字均参照相关研究文章中的相关图例。
图1b) 测量神经元或星形胶质细胞培养上清液中的IGF-I水平，±H2O2处理。
图1c) 更新：在IGF-I处理后，通过转染IGF-IR显性负突变体（IGF-IR DN）的星形胶质细胞中测量pAKT水平。
图1d) 以GFP阳性细胞培养百分比衡量，与转染IGF-IR DN的星形胶质细胞共培养的神经元存活率。
图2a) IGF-I处理后，测量±PPP（哌甲酯）处理的星形胶质细胞中的pAKT水平。
图2b) 以GFP阳性细胞培养百分比衡量，±PPP和H2O2处理的神经元存活率。
图2c) 以GFP阳性细胞培养百分比表示的神经元存活率，与星形胶质细胞共培养并±PPP和H2O2处理。
图2d) 以GFP阳性细胞培养百分比衡量，与来自前脑的神经元和星形胶质细胞共培养并±PPP和H2O2处理的神经元存活率。
图2e) 以GFP阳性细胞培养百分比衡量，与星形胶质细胞共培养并接受IGF-I、H2O2或两者共同处理的神经元存活率。
图3a) 以PI阳性细胞百分比衡量神经元死亡，±IGF-I和H2O2处理。
图3b) 以PI阴性细胞百分比表示的星形胶质细胞存活率，±IGF-I和H2O2处理。
图3c) IGF-I、H2O2或两者共同处理的星形胶质细胞中的FOXO活性。
图3d) 细胞存活率，以GFP阳性细胞百分比表示，对于转染wt或AKT不敏感突变型FOXO的星形胶质细胞，±IGF-I和H2O2处理。
图3e) IGF-I I ± H2O2处理的星形胶质细胞中的pAKT水平。
图4a) IGF-I和H2O2处理后的星形胶质细胞中测量的线粒体O2-。
图4b) IGF-I和H2O2处理后的星形胶质细胞中测量的总活性氧（ROS）。
图5a) IGF-I、H2O2或两者共同处理的星形胶质细胞中的Cu/Zn SOD（超氧化物歧化酶）水平。
图5b) IGF-I、H2O2或两者共同处理的星形胶质细胞中的Mn SOD水平。
图6a) IGF-I、H2O2或两者共同处理的星形胶质细胞中的TXNIP水平。
图6b) 转染TXNIP shRNA ± H2O2处理的星形胶质细胞存活率。
图6c) IGF-I、H2O2或两者共同处理的神经元中的TXNIP水平。
图6d) 在IGF-I、H2O2或两者共同存在的情况下，预用钙抑制剂BAPTA处理的星形胶质细胞中的TXNIP水平。
图7a) IGF-I、H2O2或两者共同处理的星形胶质细胞中的SCF（干细胞因子）mRNA。
图7b) 在H2O2存在的情况下，以IGF-I、SCF或两者共同处理的GFP阳性细胞百分比衡量神经元存活率。
图7c) ±H2O2处理的星形胶质细胞中的pERK水平，IGF-I、SCF或两者共同处理。
图7d) 来自对照组或MCAO（大脑中动脉闭塞）动物皮层（对侧或同侧皮层）的SCF和IGF-I mRNA。
图7e) 来自对照组或MCAO动物皮层（对侧或同侧皮层）的SCF蛋白水平。
Luminol) 使用Luminol（检测超氧阴离子）测量活性氧（ROS）。